Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 1, 2010
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
John Zechner
Chairman, J. Zechner & Assoc
Price
$1.210
Owned
No
BUY WEAKNESS
BUY WEAKNESS
June 22, 2009
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
Robert McWhirter
President, Selective Asset Management
Price
$1.900
Owned
Unknown
DON'T BUY
DON'T BUY
June 12, 2009
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
Benj Gallander
President, Contra the Heard Investment Letter
Price
$2.150
Owned
No
COMMENT
COMMENT
December 11, 2007
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
Robert Floyd
President, R A Floyd Management
Price
$3.660
Owned
No
HOLD
HOLD
July 5, 2007
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
Chyanne Fickes
Vice President of Investments, Stone Funds
Price
$7.310
Owned
Unknown
SELL
SELL
June 1, 2007
The whole market is going up, and this one is going down. Let someone else own it.
The whole market is going up, and this one is going down. Let someone else own it.
Kenneth P. Norquay, CMT
Partner, Castlemoore Inc.
Price
$7.220
Owned
No
SELL
SELL
May 1, 2007
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
Norman Levine
Managing Director, Portfolio Management Corp
Price
$6.290
Owned
No
DON'T BUY
DON'T BUY
April 19, 2007
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
Robert Floyd
President, R A Floyd Management
Price
$6.850
Owned
Unknown
COMMENT
COMMENT
April 17, 2007
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
Chyanne Fickes
Vice President of Investments, Stone Funds
Price
$6.990
Owned
Unknown
BUY
BUY
April 2, 2007
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
John Zechner
Chairman, J. Zechner & Assoc
Price
$6.170
Owned
Yes
DON'T BUY
DON'T BUY
March 28, 2007
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
Norman Levine
Managing Director, Portfolio Management Corp
Price
$6.380
Owned
No
DON'T BUY
DON'T BUY
March 12, 2007
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$7.200
Owned
No
DON'T BUY
DON'T BUY
March 12, 2007
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Chyanne Fickes
Vice President of Investments, Stone Funds
Price
$7.200
Owned
Yes
DON'T BUY
DON'T BUY
March 9, 2007
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$7.370
Owned
No
DON'T BUY
DON'T BUY
February 13, 2007
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Robert Floyd
President, R A Floyd Management
Price
$7.830
Owned
Unknown
Showing 1 to 15 of 140 entries